H. Nishikawa

Immunology · 2005–2020

A researcher in the Science corpus: 10 papers; trusts 7 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Immunology — 228 citations into it
• Oncology — 113 citations into it

Whom H. Nishikawa trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Shimon Sakaguchi
2. D. Pardoll
3. J. Fontenot
4. M. Gavin
5. D. Gabrilovich
6. E. Shevach
7. Sergio A. Quezada
8. J. P. Rasmussen

Who trusts H. Nishikawa overall

1. S. Formenti
2. D. Campbell
3. Atsushi Tanaka

Papers from H. Nishikawa's perspective

Ordered by how strongly the researchers H. Nishikawa trusts endorse each paper. Same corpus, a different order for every researcher.

1. Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells (Journal of Experimental Medicine)
2. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
3. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. (Journal of Clinical Investigation)
4. Does the immune system see tumors as foreign or self? (Annual Review of Immunology)
5. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (Nature Reviews. Cancer)
6. Foxp3-dependent programme of regulatory T-cell differentiation (Nature)
7. Regulatory T cells in tumor immunity (International Journal of Cancer)
8. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid (Journal of Experimental Medicine)
9. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (Nature Medicine)
10. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells (Nature)

Their papers

• Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota (2013) — 2,675 citations
• Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). (2020) — 649 citations
• The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies (2020) — 645 citations
• Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? (2019) — 888 citations
• Regulatory T cells in cancer immunosuppression — implications for anticancer therapy (2019) — 1,316 citations
• PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer (2019) — 873 citations
• Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers (2016) — 790 citations
• Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans (2013) — 619 citations
• Regulatory T cells in tumor immunity (2010) — 955 citations
• Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. (2005) — 2,404 citations